CARL Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025
Revenue
18.9M
+17.5%
16.1M
+6.3%
15.2M
+16.0%
13.1M
Cost of Revenue
4.4M
+19.2%
3.7M
+3.8%
3.6M
+13.0%
3.1M
Gross Profit
14.5M
+17.0%
12.4M
+7.0%
11.6M
+16.9%
9.9M
Operating Expenses
25.6M
+17.9%
21.7M
+3.7%
20.9M
+10.4%
19.0M
R&D
6.0M
+16.6%
5.2M
-1.6%
5.3M
+18.4%
4.4M
SG&A
19.5M
+18.2%
16.5M
+5.5%
15.7M
+7.9%
14.5M
Operating Income
-11036000
-19.0%
-9276000
+0.5%
-9318000
-3.1%
-9035000
EBITDA
-10906000
-18.8%
-9177000
+0.5%
-9220000
-3.0%
-8953000
Net Income
-10510000
-20.9%
-8696000
-1.0%
-8613000
-1.0%
-8526000
EPS (Basic)
$-0.39
-21.9%
$-0.32
+0.0%
$-0.32
+20.0%
$-0.40
EPS (Diluted)
$-0.39
-21.9%
$-0.32
+0.0%
$-0.32
+20.0%
$-0.40
Shares (Diluted)
27.2M
+1.3%
26.8M
-0.3%
26.9M
+27.7%
21.1M
Carlsmed (CARL) โ€” Financials